|
|
SFX by Ex Libris Inc.
|
List of services to meet your request
|
|||||||
|
|||||||
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=sD14F5B28-5952-11EF-BF09-2C2585CE164B&I=39IZM&T=&OP=Display&O=html&O1=14982163&O2=4520000000000844&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3DShould%2520We%2520%25E2%2580%259CPROpel%25E2%2580%259D%2520Olaparib%2520Forward%2520for%2520Metastatic%2520Castration-Resistant%2520Prostate%2520Cancer%253F%26rft.au%3DHussain%252C%2520Maha%26rft.au%3DVanderWeele%252C%2520David%2520J.%26rft.date%3D2022-09-01%26rft.eissn%3D2766-5526%26rft.externalDBID%3Dn%252Fa%26rft.externalDocID%3D10_1056_EVIDe2200154%26rft.genre%3Darticle%26rft.issn%3D2766-5526%26rft.issue%3D9%26rft.jtitle%3DNEJM%2520evidence%26rft.volume%3D1%26rft_id%3Dinfo%253Adoi%252F10.1056%252FEVIDe2200154%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-OVID_JOURNALS_AT_OVID-getFullTxt-object,2-DOI-getDOI-object,3-COBIB_SI_LCL-getHolding-object,4-REFWORKS_EXPORT_TOOL-getReference-object,5-GOOGLE_SCHOLAR_FREE-getWebSearch-object,6-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=0.830214&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:14982163-sD14F5B28-5952-11EF-BF09-2C2585CE164B" timestamp="2024-08-13T11:02:51Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:4520000000000844</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>Should We “PROpel” Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?</jnl:atitle>
<jnl:jtitle>NEJM Evidence</jnl:jtitle>
<jnl:date>2022-08-23</jnl:date>
<jnl:issn>2766-5526</jnl:issn>
<jnl:volume>1</jnl:volume>
<jnl:issue>9</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>2766-5526</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:e3793a5d03313f6198b2ddcbf727d9f948af077a</ctx:identifier>
<ctx:identifier>urn:UUID:sD14F5B28-5952-11EF-BF09-2C2585CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)